Australia's Rhythm Biosciences jumps most in 3 weeks on cancer blood test expansion
06/01/2022 01:04
** Shares of cancer diagnostic co Rhythm Biosciences
RHY.AX jump as much as 9.4% to A$1.630, posting their biggest
intraday pct gain since Dec. 14, 2021
** RHY confirms https://www.asx.com.au/asxpdf/20220106/pdf/454s8m5jthwsw7.pdf
expansion of CE Mark registration that will allow co's
ColoSTAT, a blood test for the detection of colorectal cancer,
to be marketed and sold within Great Britain and Northern
Ireland
** Stock hits highest level since Dec. 30, 2021
** Rhythm Biosciences rose ~77.6% in 2021
(Reporting by Upasana Singh in Bengaluru)
((Upasana.Singh@thomsonreuters.com))
Recent news on Rhythm Biosciences
See all newsBrief: Rhythm Biosciences Says Gavin Fox-Smith Resigns As Chair
Brief: Rhythm Biosciences Announces Appointment Of Non-Executive Directors
Australia's Rhythm Biosciences rises on accelerating commercialisation of cancer test
Brief: Rhythm Biosciences Executes Distribution Agreement For Genetype
Brief: Rhythm Biosciences Seeks Trading Halt